Mapping EGFR1 mutations in patients with lung adenocarcinoma

Diagnostic Molecular Pathology

Volumn 19, Issue 4, 2010, Pages 209-217

  Vlastos, Fotis ^a   Zinszner, Julie ^b   Hussenet, Thomas ^c   Du Manoir, Stanislas ^c   Vordonis, Leonidas ^b   Nikolakopoulou, Sofia ^a   Hardavella, Georgia ^d   Lacomme, Stéfanie ^b   Vignaud, Jean Michel ^b   Martinet, Nadine ^e  

^a Centre of Respiratory Insufficiency   (United States)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d UNIVERSITY OF ATHENS   (Greece)

^e CNRS 6001   (France)

Author keywords

adenocarcinoma; EGFR1 mutations; enzymatic method; exons

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE MAPPING; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADENOCARCINOMA; AGED; COHORT STUDIES; DNA; DNA RESTRICTION ENZYMES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650509859     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181d32605     Document Type: Article

References (23)

1. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest. 2007;117: 2051-2058. (Pubitemid 47224766)
2. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(10 suppl):2379-2385. (Pubitemid 23156828)
3. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. 2009;2:2.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med. 2004;350: 2129-2139. (Pubitemid 38637993)
5. Vlastos F, Lacomme S, Wild P, et al. Do evolving practices improve survival in operated lung cancer patients? A biobank may answer. J Thorac Oncol. 2009;4:505-511.
6. Vlastos F, Hillas G, Vidal P, et al. Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort. J Thorac Oncol. 2009;4:1259-1263.
7. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as firstline therapy in advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:303-310. (Pubitemid 351654331)
8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
9. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13 306-13 311. (Pubitemid 39209661)
10. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 2004;64:8919-8923. (Pubitemid 39665498)
11. Matsuo K, Ito H, Yatabe Y, et al. Risk factors differ for non-smallcell lung cancers with and without EGFR mutation: Assessment of smoking and sex by a case-control study in Japanese. Cancer Sci. 2006;98:96-101. (Pubitemid 44803926)
12. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817-1824. (Pubitemid 350002184)
13. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006;11:190-198. (Pubitemid 44087117)
14. Katsuhiko E, Akimitsu K, Hidefumi S, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer. 2005;50:375-384. (Pubitemid 43300637)
15. Cetin Z, Ozbilim G, Erdogan A, et al. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol. 2009. [Epub ahead of print].
16. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist. 2005;10:579-589.
17. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3 Pt 1):839-844. (Pubitemid 43259866)
18. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520. (Pubitemid 47050841)
19. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839-844. (Pubitemid 43259866)
20. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12: 3908-3914. (Pubitemid 44078074)
21. Greulich H, Chen T-H, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutations. PLoS Med. 2005;2:e313. (Pubitemid 41735785)
22. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006;66:8163-8171.
23. Mulloy R, Ferrand A, Kim Y, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007;67:2325-2330. (Pubitemid 46424253)